Used as a potent and selective inhibitor of Janus kinase 1 (JAK1), this compound is primarily investigated for its role in modulating immune responses. It shows promise in the treatment of autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Due to its selectivity for JAK1 over other JAK family members, it may offer improved safety profiles with reduced off-target effects. It is also employed in research settings to study JAK-STAT signaling pathways and their impact on cytokine-mediated cellular processes. Its structure allows for good oral bioavailability, making it suitable for development as an oral therapeutic agent.